FUFigen Ugrasbul

Figen Ugrasbul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Figen Ugrasbul has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Karen L Kover

    Section of Endocrinology & Diabetes, Children’s Mercy Hospital, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA

    1 shared publication
  • Pei Ying Tong

    Section of Endocrinology & Diabetes, Children’s Mercy Hospital, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA

    1 shared publication
  • Wayne V Moore

    Section of Endocrinology & Diabetes, Children’s Mercy Hospital, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA

    1 shared publication

Latest Publications

  • Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat

    by Figen Ugrasbul, Wayne V Moore, Pei Ying Tong, Karen L Kover

    Anti-CD25 and mycophenolate mofetil (MMF) treatment of patients with new-onset diabetes is currently being tested as one of the trials in TrialNet. We tested the effectiveness of MMF and anti-CD25 in preventing autoimmune diabetes in the diabetes-resistant biobreeding (DRBB) rat. Autoimmune diabetes in the DRBB rat was induced with a Treg cell depletion regimen starting at 24-26 d of age. Treatment was started on the first day of the depletion regimen in the following groups: (i) control (vehicle); (ii) MMF 25 mg/kg/d intramuscularly daily for 8 wk; (iii) anti-CD25 0.8 mg/kg/d intraperitoneally 5 d/wk for 3 wk; and (iv) combination of MMF and anti-CD25. In a second set of experiments, treatments were started on day 5 of the depletion regimen (delayed treatment) with groups 1, 3, and 4. Rats that had diabetes-free survival for at least 30 d after the treatment was stopped underwent a second Treg depletion (redepletion). In each of the three treatment groups (n = 10/group), onset of diabetes was delayed or prevented in 20, 40 and 80% in groups 2, 3, and 4, respectively. After redepletion, diabetes-free survival was unchanged in group 2 and decreased to 10 and 30% in groups 3 and 4, respectively. With delayed treatment, groups 3 and 4 had 33 and 50% diabetes-free survival that decreased to 0 and 33% after redepletion. MMF and anti-CD25 alone or in combination are effective in delaying and preventing diabetes in the DRBB rat especially if treatment is started before stimulation and expansion of the autoreactive T cells.